Patents Assigned to Emory University
  • Methods of sequencing nucleic acids in mixtures and compositions related thereto
    Patent number: 11203750
    Abstract: This disclosure relates to analyzing the end-to-end sequence and the relative distributions in heterogeneous mixtures of polynucleotides and methods and enabling reagents related thereto.
    Type: Grant
    Filed: February 1, 2019
    Date of Patent: December 21, 2021
    Assignees: Emory University, The Johns Hopkins University
    Inventors: Mark C. Emerick, William S. Agnew
  • N4-hydroxycytidine and derivatives and anti-viral uses related thereto
    Patent number: 11197882
    Abstract: This disclosure relates to certain N4-hydroxycytidine derivatives, pharmaceutical compositions, and methods related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of viral infections, such as Eastern, Western, and Venezuelan Equine Encephalitis (EEE, WEE and VEE, respectively), Chikungunya fever (CHIK), Ebola, Influenza, RSV, and Zika virus infection with the disclosed compounds.
    Type: Grant
    Filed: December 7, 2018
    Date of Patent: December 14, 2021
    Assignee: Emory University
    Inventors: George R. Painter, Gregory R. Bluemling, Michael G. Natchus, David Guthrie
  • Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
    Patent number: 11192914
    Abstract: This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses in treating infectious diseases, viral infections, and cancer, where the nucleotide or nucleoside is defined by Formula I below,
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: December 7, 2021
    Assignee: Emory University
    Inventors: Gregory Bluemling, Abel De La Rosa, George Painter, Damien Kuiper, Alexander Kolykhalov
  • Ocular monitoring headset
    Patent number: 11185224
    Abstract: A system for monitoring ocular movement can comprise a housing, a plurality of light sources, at least one imager, and a controller. The housing can define a cavity configured to allow each eye of a patient to view an interior region of the housing. The plurality of light sources can be oriented within the interior region of the housing. The at least one imager can be oriented to capture an image of an eye of a patient during an evaluation. The at least one controller can comprise at least one processor and a non-transitory computer readable medium storing instructions. The instructions can be executed by the processor and cause the controller to receive image data from the at least one imager and illuminate the plurality of light sources in a predetermined and reconfigurable sequence.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: November 30, 2021
    Assignees: Emory University, Georgia Tech Research Corporation
    Inventors: Ghassan AlRegib, Yousuf M. Khalifa, Melvin J. Mathew, Dogancan Temel
  • Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto
    Patent number: 11179501
    Abstract: The disclosure relates to compounds and compositions for bone formation, fracture treatment, bone grafting, bone fusion, cartilage maintenance and repair and methods related thereto. In certain embodiments, the disclosure relates to compositions comprising one or more compound(s) disclosed herein, such as clotrimazole, honokiol, magnolol, tacrolimus, pimecrolimus, sirolimus, everolimus, temsirolimus, spironolactone, fluticasone, fluticasone propionate, fluticasone furoate, linezolid, telmisartan, chlorambucil, retinol, isotretinoin, acitretin, etretinate, retinoic acid (tretinoin), teniposide, mitomycin C, cytarabine, decitabine, vinblastine, vincristine, vindesine, vinorelbine, valrubicin, doxorubicin, daunorubicin, epirubicin, idarubicin, mitoxantrone, pixantrone, plicamycin, pazopanib, topotecan, camptothecin, irinotecan, sunitinib, derivatives, or salt thereof, for use in bone growth processes.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: November 23, 2021
    Assignee: Emory University
    Inventors: Scott D. Boden, Sreedhara Sangadala
  • Polymers of polyoxometalates and hydroxy-terminated monomer units and uses in degrading noxious agents
    Patent number: 11174352
    Abstract: This disclosure relates to polymers and polymer compositions having monomer units of polyoxometalates and monomer units comprising hydroxy-terminated molecules such as branched molecules or dendrimers and uses in degradation, decontamination, and deodorization. In certain embodiments, the hydroxy-terminated branched molecules or dendrimers comprise terminal 1,1-tris(hydroxymethyl)methyl or 1,1,1-tris(hydroxyalkyl)methyl groups. In certain embodiments, the hydroxy-terminated molecule is N,N?,N?-tris[tris(hydroxymethyl) methyl]-1,3,5-benzenetricarboxamide.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: November 16, 2021
    Assignee: Emory University
    Inventors: Craig Hill, Kevin Sullivan
  • Substituted nucleotides and nucleosides for treating viral infections
    Patent number: 11166973
    Abstract: This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses in treating viral infections, where the base of the nucleotide or nucleoside contains at least one thiol, thione or thioether.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: November 9, 2021
    Assignee: Emory University
    Inventors: Dennis C. Liotta, George R. Painter, Gregory R. Bluemling, Abel de la Rosa
  • Multivalent enterovirus vaccine compositions and uses related thereto
    Patent number: 11160857
    Abstract: This disclosure relates to multivalent enterovirus vaccine compositions and uses related thereto. In certain embodiments, the disclosure relates to vaccine compositions comprising multivalent, mixtures of enterovirus (for example HRV) serotypes or recombinantly produced variants or recombinantly produced viral capsid proteins. In certain embodiments, the disclosure relates to methods of immunization comprising administering an effective amount of compositions disclosed herein to a subject diagnosed with, exhibiting symptoms of, or at risk of an enterovirus infection.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: November 2, 2021
    Assignees: Emory University, Children's Healthcare of Atlanta, Inc.
    Inventors: Martin L. Moore, Sujin Lee, Minh Trang Nguyen
  • Systems and methods of IV infiltration detection
    Patent number: 11154246
    Abstract: As an IV infiltration occurs and fluid leaks into surrounding tissues, several physiological changes are expected locally. The systems and methods described herein provide a scalable automated IV infiltration detection device to provide medical staff an early warning of a possible infiltration such that they can respond accordingly. The systems and methods capture the physiological state of the user at or around a peripheral catheter insertion site by incorporating one or more modalities of wearable sensing, processing the data collected from these wearable sensors, detecting the presence of extravascular fluid, and providing an indication to a medical professional.
    Type: Grant
    Filed: June 26, 2017
    Date of Patent: October 26, 2021
    Assignees: Georgia Tech Research Corporation, Children's Healthcare of Atlanta, Inc., Emory University
    Inventors: Omer Inan, Jambu Jambulingam, Kevin Maher, Russell Scott McCrory, Leanne West, Sinan Hersek, Samer Mabrouk
  • USE OF MACHINE LEARNING MODELS FOR PREDICTION OF CLINICAL OUTCOMES
    Publication number: 20210327540
    Abstract: The present disclosure describes methods and systems for predicting if a subject has an increased risk of having or developing one or more clinical outcomes, including prior to the detection of symptoms thereof and/or prior to onset of any detectable symptoms thereof. The present disclosure also describes a method of generating a model for predicting one or more clinical outcomes.
    Type: Application
    Filed: August 16, 2019
    Publication date: October 21, 2021
    Applicants: Henry M. Jackson Foundation for the Advancement of Military Medicine, Naval Medical Research Center, Duke University Medical Center, Emory University
    Inventors: Seth A Schobel, Vivek Khatri, Felipe Lisboa, Matthew J. Bradley, Christopher J. Dente, Timothy Buchman, Allan D. Kirk, Jonathan A. Forsberg, Todd V. Brennan, Eric A. Elster
  • Specific binding agents to varicella-zoster virus and uses related thereto
    Patent number: 11147870
    Abstract: This disclosure relates to specific binding agents to varicella-zoster virus proteins or glycoproteins. In certain embodiments the specific binding agents are antibodies and binding fragments thereof disclosed herein. In certain embodiments, this disclosure relates to methods of treating or preventing a varicella-zoster infection comprising administering an effective amount of a specific binding agent disclosed herein to a subject in need thereof.
    Type: Grant
    Filed: April 25, 2019
    Date of Patent: October 19, 2021
    Assignee: Emory University
    Inventors: Rafi Ahmed, Nicole Sullivan
  • N4-hydroxycytidine and derivatives and anti-viral uses related thereto
    Patent number: 11147826
    Abstract: This disclosure relates to certain N4-hydroxycytidine derivatives, pharmaceutical compositions, and methods related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of viral infections, such as Eastern, Western, and Venezuelan Equine Encephalitis (EEE, WEE and VEE, respectively), Chikungunya fever (CHIK), Ebola, Influenza, RSV, and Zika virus infection with the disclosed compounds.
    Type: Grant
    Filed: December 7, 2018
    Date of Patent: October 19, 2021
    Assignee: Emory University
    Inventors: George R. Painter, Gregory R. Bluemling, Michael G. Natchus, David Guthrie
  • Methods and compositions for managing vascular conditions
    Patent number: 11149274
    Abstract: This disclosure relates to methods and compositions for managing vascular conditions by targeting microRNA. In certain embodiments, the disclosure relates to antisense, RNA interference, and blocking oligonucleotide therapeutic compositions and uses related thereto.
    Type: Grant
    Filed: December 3, 2019
    Date of Patent: October 19, 2021
    Assignees: Emory University, Georgia Tech Research Corporation
    Inventors: Hanjoong Jo, Dongju Son, Wakako Takabe, Sandeep Kumar, Haiwei Qiu, Chanwoo Kim
  • Expression of chimeric polypeptide with variable lymphocyte receptors on immune cells and uses for treating cancer
    Patent number: 11136369
    Abstract: This disclosure relates to recombinant cellular expression of chimeric proteins with peptide sequences derived from lymphocyte receptors and uses for treating cancer. In certain embodiments, the disclosure relates to a recombinant vector comprising a nucleic acid that encodes a chimeric protein with a segment with a targeting moiety based on a variable lymphocyte receptor (VLR) capable of binding a tumor associated antigen and a segment with a T cell signal transduction subunit. In certain embodiments, the recombinant vectors are used in immune based cancer treatments.
    Type: Grant
    Filed: May 1, 2019
    Date of Patent: October 5, 2021
    Assignees: Emory University, Children's Healthcare of Atlanta, Inc.
    Inventors: H. Trent Spencer, Christopher B. Doering, Brantley R. Herrin, Max Dale Cooper
  • Particles coated with catalysts useful for splicing nucleic acids
    Patent number: 11136595
    Abstract: This disclosure relates to compositions comprising particles conjugated to one or more catalytically cleaving nucleic acids and optionally an RNA ligating enzyme. In certain embodiments, particles reported herein are used for splicing nucleic acid sequences.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: October 5, 2021
    Assignee: Emory University
    Inventors: Khalid Salaita, Jessica Petree, Kevin Yehl
  • Methods of culturing and characterizing antibody secreting cells
    Patent number: 11125757
    Abstract: This disclosure relates to methods of culturing and characterizing antibody secreting cells. In certain embodiments, this disclosure relates to methods of isolating antibody secreting cells, e.g., long lived plasma cells, replicating the isolated cells in growth media disclosed herein, and determining the nucleic acids sequences in the cells that encode the produced antibodies.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: September 21, 2021
    Assignee: Emory University
    Inventors: Frances Eun-Hyung Lee, Ignacio Sanz, Doan C. Nguyen
  • Methods of reducing liver PD-1-expressing CD8+ T cells using PD-1 Fc fusion proteins that bind Fc receptors
    Patent number: 11124569
    Abstract: The present invention relates to methods of reducing liver PD-1-expressing CD8+ T cells using PD-1 Fc fusion proteins that bind Fc receptors, as well as diagnostic, prognostic, therapeutic methods and compositions related thereto.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: September 21, 2021
    Assignees: Dana-Farber Cancer Institute, Inc., President And Fellows Of Harvard College, Emory University
    Inventors: Gordon J. Freeman, Rafi Ahmed, Arlene H. Sharpe, Masao Hashimoto, Hyun T. Jin
  • 2-amino-N'-benzylideneacetohydrazides and derivatives for the management of CFTR protein mediated diseases
    Patent number: 11116736
    Abstract: This disclosure relates to methods of treating or preventing cystic fibrosis transmembrane conductance regulator (CFTR) mediated diseases such as cystic fibrosis, chronic obstructive pulmonary disease, chronic pancreatitis, chronic bronchitis, asthma, mucus formation, comprising administering an effective amount of a 2-amino-N?-benzylidene-acetohydrazide compound or derivative thereof to a subject in need thereof. In certain embodiments, the 2-amino-N?-benzylidene-acetohydrazide compound is ((E)-N?-(3,5-dibromo-2,4-dihydroxybenzylidene)-2-(m-tolylamino)acetohydrazide; or (E)-N?-(3,5-dibromo-2,4-dihydroxybenzylidene)-2-(p-tolylamino)acetohydrazide.
    Type: Grant
    Filed: January 3, 2020
    Date of Patent: September 14, 2021
    Assignees: Emory University, Bar-Ilan University, Children's Healthcare of Atlanta, Inc.
    Inventors: Nael McCarty, Guiying Cui, Hanoch Senderowitz, Netaly Khazanov
  • Pyrazoline dihydroquinolones, pharmaceutical compositions, and uses
    Patent number: 11117882
    Abstract: This disclosure relates to pyrazoline dihydroquinolone derivatives, pharmaceutical compositions, and uses. In certain embodiments, the compounds are selective NMDA receptor inhibitors and are useful in therapeutic methods related thereto. In certain embodiments, this disclosure relates to pharmaceutical compositions comprising a compound of the following formula: or salts, esters, or prodrugs thereof, as provided herein.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: September 14, 2021
    Assignee: Emory University
    Inventors: Timothy M. Acker, Dennis C. Liotta, Stephen F. Traynelis, Yao Jing
  • Lipid disulfide prodrugs and uses related thereto
    Patent number: 11090316
    Abstract: This disclosure relates to lipid disulfide prodrugs and in particular to lipid disulfide phosphodiester nucleosides and derivatives thereof, pharmaceutical compositions, and uses related thereto. According to one embodiment of the disclosure there is provided a compound of Formula I, or pharmaceutically acceptable salts or derivatives thereof, wherein substituents are disclosed herein.
    Type: Grant
    Filed: June 12, 2020
    Date of Patent: August 17, 2021
    Assignee: Emory University
    Inventors: Dennis Liotta, Kyle Giesler